Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$55.15 USD
-0.25 (-0.45%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $55.16 +0.01 (0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
HALO 55.15 -0.25(-0.45%)
Will HALO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HALO
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks.com featured highlights include Amazon.com, Halozyme Therapeutics, Tenet Healthcare and Atmos Energy
4 Stocks With Impressive Interest Coverage Ratio to Buy Now
J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs
Other News for HALO
Halozyme to Report Second Quarter 2024 Financial and Operating Results
Healthcare 2024 Second Half Outlook
Laughing Water Capital Q2 2024 Letter
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
Halozyme price target raised by $10 at Benchmark, here's why